Inplavia

Inplavia Uses, Dosage, Side Effects, Food Interaction and all others data.

Inplavia is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (Arimidex ™), letrozole (Femara ™) and exemestane (Aromasin ™).

Inplavia
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Inplavia
Availability	Prescription only
Generic	Exemestane
Exemestane Other Names	Exemestane, Exemestano, Exemestanum
Related Drugs	Arimidex, Ibrance, Femara, Aromasin, Faslodex, Verzenio, Afinitor, Xeloda, Herceptin, Lynparza
Type
Formula	C₂₀H₂₄O₂
Weight	Average: 296.4034 Monoisotopic: 296.177630012
Protein binding	90% (mainly α1-acid glycoprotein and albumin)
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Romania
Last Updated:	September 19, 2023 at 7:00 am

Uses

Inplavia is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.

For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Inplavia is also used to associated treatment for these conditions: Early Breast Cancer, Refractory, advanced Breast cancer

How Inplavia works

Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Inplavia is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It irreversibly binds to the active site causing permanent inhibition necessitating de novo synthesis to restore enzymatic function. Inplavia significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on the adrenal biosynthesis of corticosteroids or aldosterone. This reduction in serum and tumor concentrations of estrogen delays tumor growth and disease progression. Inplavia has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.